18 and older, female only, with Recurrent Fallopian Tube Carcinoma or Recurrent Ovarian Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Patients With a Confirmed Tumor Response, Defined as Complete Response or Partial Response Estimated Using Response Evaluation Criteria in Solid Tumors 1.1 CriteriaPrimary· 24 weeks
Estimated by the number of successes divided by the total number of evaluable patients. Ninety-five percent confidence intervals for the true success proportion will be calculated according to the exact Binomial method. The primary analysis will pool across all patients, and tumor response rate by treatment arm will also be looked at in an exploratory fashion.
Group
Value
95% CI
Arm A (Avatar-directed Paclitaxel)
0
Arm B (Avatar-directed Gemcitabine Hydrochloride)
0
Arm D (Avatar-directed Topotecan Hydrochloride)
0
Number of Patients Experiencing Grade 3+ Adverse Events (AE)Secondary· 9 months
Maximum grade for each type of AE will be recorded for each patient, and frequency tables will be reviewed to determine AE patterns.
Group
Value
95% CI
Arm A (Avatar-directed Paclitaxel)
1
Arm B (Avatar-directed Gemcitabine Hydrochloride)
1
Arm D (Avatar-directed Topotecan Hydrochloride)
4
Overall Survival (OS)Secondary· 25 months
OS will be estimated using the method of Kaplan-Meier. Analysis will be conducted with all arms of Avatar-directed chemotherapy pooled.
PFS will be estimated using the method of Kaplan-Meier. Analysis will be conducted with all arms of Avatar-directed chemotherapy pooled.
Group
Value
95% CI
Arm A (Avatar-directed Paclitaxel)
7.9
NA – NA
Arm B (Avatar-directed Gemcitabine Hydrochloride)
8.7
NA – NA
Arm D (Avatar-directed Topotecan Hydrochloride)
3.0
1.9 – NA
Number of Patients With a Partial or Confirmed ResponseSecondary· 9 months
The Chi-square or Fisher's Exact test will be used to compare the response rates between patients who did or did not receive bevacizumab treatment. The response rates will also be reported by treatment type.
Group
Value
95% CI
Arm A (Avatar-directed Paclitaxel)
0
Arm B (Avatar-directed Gemcitabine Hydrochloride)
0
Arm D (Avatar-directed Topotecan Hydrochloride)
0
Adverse events — posted to ClinicalTrials.gov
Time frame: 25 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Arm A (Avatar-directed Paclitaxel)
Serious: 1/2 (50%)
Deaths: 1/2
Arm B (Avatar-directed Gemcitabine Hydrochloride)
Serious: 0/1 (0%)
Deaths: 1/1
Arm D (Avatar-directed Topotecan Hydrochloride)
Serious: 3/9 (33%)
Deaths: 6/9
Serious adverse events (9 terms)
Reaction
System
Arm A (Avatar-directed Pac…
Arm B (Avatar-directed Gem…
Arm D (Avatar-directed Top…
Colonic obstruction
Gastrointestinal disorders
—
—
—
Gastric perforation
Gastrointestinal disorders
—
—
—
Skin infection
Infections and infestations
—
—
—
Creatinine increased
Investigations
—
—
—
Hyponatremia
Metabolism and nutrition disorders
—
—
—
Neoplasms benign, mal, uncpec - Oth spec
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
This phase II trial studies how well Avatar-directed chemotherapy works in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that does not respond to platinum anti-cancer drugs. Drugs used in chemotherapy, such as paclitaxel, gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Using an Avatar, a living tumor sample with similar genetic characteristics to the original tumor, may help determine which chemotherapy is most effective.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and
· Phase 2
· not yet recruiting
NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable
· Phase 1
· not yet recruiting
NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore
· Phase 3
· not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
· EARLY_PHASE1
· not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance
· Phase 2
· not yet recruiting
Other recruiting trials for Recurrent Fallopian Tube Carcinoma
Currently open trials in the same condition.
NCT06855706 — An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV
· NA
· recruiting
NCT06483048 — MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
· Phase 1
· recruiting
NCT05231122 — Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
· Phase 2
· recruiting
NCT06295965 — Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
· recruiting
NCT05920798 — Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
· Phase 1, PHASE2
· recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men
· NA
· not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
· not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance,
· NA
· not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE)
· NA
· recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 5 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02312245.